ViroPharma Incorporated (VPHM)

[surf1944]

7:32AM ViroPharma provides 2010 Cinryze (C1 Esterase Inhibitor [Human]) outlook; expects sales will be toward high end of previous guidance of $90-$95 mln (VPHM) 8.75 : Co Provides its 2010 Cinryze (C1 Esterase Inhibitor [Human]) outlook. Co states, "In 2009 we successfully launched Cinryze (C1 esterase inhibitor [human]), the first and only drug approved to prevent HAE attacks. Thanks to meticulous execution by our team, we were able to provide Cinryze during 2009 to over 400 patients who are now actively preventing their attacks. We are pleased to announce that for 2009, we expect our net Cinryze sales will be toward the high end of our previous guidance range of $90 to $95 million, placing Cinryze among the best ever launches of an ultra orphan drug product... Further, we recently conducted a successful meeting with the FDA on our industrial scale initiative where we were able to confirm our previous expectations of the path forward for this significantly expanded manufacturing process. As a result, we are announcing 2010 Cinryze net sales guidance of between $145 and $165 mln, which represents tremendous revenue growth over 2009. Although we anticipate that we will be profitable in 2010, we will provide our full guidance later in the first quarter of this year. Finally, I am pleased to announce we have increased our projection of U.S. HAE peak year Cinryze sales to between $350 and $450 mln. Our objective continues to be to ensure that every patient who can benefit from Cinryze will have access to this important drug."